When was Cinclus Pharma founded?

Cinclus Pharma was founded in 2014 and raised its 1st funding round 6 years after it was founded.

Where is Cinclus Pharma located?

Cinclus Pharma is headquartered in Gothenburg, Sweden.

How many employees does Cinclus Pharma have?

As of Aug 31, 2026, the latest employee count at Cinclus Pharma is 27.

Is Cinclus Pharma a funded company?

Cinclus Pharma is a funded company, having raised a total of $25.7M across 2 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Mar 04, 2020.

When was the latest funding round of Cinclus Pharma?

Cinclus Pharma's latest funding was a $***** Series B round on Apr 19, 2022, with participation from 5 investors.

Where does Cinclus Pharma rank among its competitors?

Cinclus Pharma ranks 89th amongst 2551 active competitors, of which 861 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Cinclus Pharma?

Cinclus Pharma's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Cinclus Pharma - 2026 Company Profile, Team, Funding & Competitors

Cinclus Pharma is a public company based in Gothenburg (Sweden), founded in 2014 by Marek Poszepczynski. It operates as a Developer of small molecules for the treatment of gastric acid-related diseases. Cinclus Pharma has raised $25.7M in funding from Fjarde AP-fonden and Trill impact. The company has 2551 active competitors, including 861 funded and 643 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of small molecules for the treatment of gastric acid-related diseases. The lead candidate of the company is Linaprazan glurate a potassium-competitive acid blocker (P-CAB) and a prodrug of linaprazan for the treatment of erosive Gastroesophageal reflux disease (eGERD).

Website: cincluspharma.com
Email ID: *****@cincluspharma.com

Key Metrics

Founded Year

2014

Location

Gothenburg, Sweden

Stage

Public

Total Funding

$25.7M in 2 rounds

Latest Funding Round

Series B, Apr 19, 2022, $*****

Investors

Fjarde AP-fonden & 7 more

Ranked

89^th among 2551 active competitors

Employee Count

27 as on Aug 31, 2026

Similar Companies

Ironwood Pharma & 154 more

Exit Details

Public

View Cinclus Pharma's full profile

Cinclus Pharma got listed on Jun 20, 2024.

Click here to take a look at Cinclus Pharma's IPO in detail

Cinclus Pharma has raised a total funding of $25.7M over 2 rounds. Its first funding round was on Mar 04, 2020. Its latest funding round was a Series B round on Apr 19, 2022 for $*****. 5 investors participated in its latest round. Cinclus Pharma has 6 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Cinclus Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 19, 2022	7848041	Series B	8779347	5477207	9363319	7096587
Mar 04, 2020	5954173	Series B	1414711	2712661	Fjarde AP-fonden	Jonas Sjögren & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Cinclus Pharma's funding rounds and investors

The founders of Cinclus Pharma is Marek Poszepczynski.

Here are the details of Cinclus Pharma's key team members:

Marek Poszepczynski: Co-Founder of Cinclus Pharma.
Contact Info: 1 email address and 1 phone number

View details of Cinclus Pharma's Founder profiles and Board Members

Cinclus Pharma's employee count trend

Cinclus Pharma has 27 employees as of Aug 26. Here is Cinclus Pharma's employee count trend over the years:

Uncover Cinclus Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cinclus Pharma include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Cinclus Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
89th	Cinclus Pharma 2014, Gothenburg (Sweden), Public	Developer of small molecules for the treatment of gastric acid-related diseases	$25.7M	Fjarde AP-fonden, Irrus Investments & 6 others	62/100